Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-07-09

Clinical Trial Update: Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study of temozolomide in patients with poor-risk or refractory acute myeloid leukemia has been completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Temozolomide (Temozolomide)

Snippet

Sponsor: Bruno C. Medeiros | Conditions: Leukemia, Myeloid | Phase 2 | Status: COMPLETED | Results posted: 2014-07-09